Charles River Laboratories International (CRL) Positioned to Benefit from Preclinical Research Activity and Biotech Funding Recovery

3 weeks ago 9

Soumya Eswaran

Fri, April 10, 2026 astatine 8:24 AM CDT 3 min read

ClearBridge Investments, a planetary equity manager, precocious published first-quarter 2026 commentary for its “Small Cap Growth Strategy”. A transcript of the missive tin beryllium downloaded here. The opening of 2026 highlighted the value of narratives, arsenic the rapidly changing technological and geopolitical dynamics influenced marketplace direction, starring the Russell 2000 Growth Index to diminution by 2.8% for the quarter. Despite this, small-cap stocks continued to execute well. Market returns diversified successful the archetypal quarter, pursuing a play of marketplace concentration, favoring smaller-cap, value-oriented, and cyclical sectors. Concerns regarding the AI superior expenditure rhythm led to accrued assemblage dispersion. The ClearBridge Small Cap Growth Strategy outperformed its Russell 2000 Growth Index benchmark owed to beardown banal selection, peculiarly successful industrials and user staples. The Strategy remains focused connected identifying companies with sustainable, unsocial maturation drivers, portion reevaluating companies that whitethorn beryllium affected by caller technology. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2026.

In its first-quarter 2026 capitalist letter, ClearBridge Small Cap Growth Strategy highlighted stocks specified arsenic Charles River Laboratories International, Inc. (NYSE:CRL) arsenic its recently acquired position. Charles River Laboratories International, Inc. (NYSE:CRL) is simply a declaration probe enactment that provides cause discovery, development, and information investigating services to pharmaceutical and biotechnology firms. On April 9, 2026, Charles River Laboratories International, Inc. (NYSE:CRL) closed astatine $175.55 per share. One-month instrumentality of Charles River Laboratories International, Inc. (NYSE:CRL) was 12.92%, and its shares gained 75.99% implicit the past 52 weeks. Charles River Laboratories International, Inc. (NYSE:CRL) has a marketplace capitalization of $8.66 billion.

ClearBridge Small Cap Growth Strategy stated the pursuing regarding Charles River Laboratories International, Inc. (NYSE:CRL) successful its Q1 2026 capitalist letter:

"We continued to present beardown caller thought procreation with 8 caller portfolio additions successful the quarter. Charles River Laboratories International, Inc. (NYSE:CRL), successful the wellness attraction sector, is the starring preclinical CRO providing indispensable cause probe services to biopharmaceutical customers. Its standard and integrated level presumption the institution to payment disproportionately arsenic preclinical probe enactment and biotech backing recover."

Among Mid-Cap Stocks Insiders Were Buying successful Q1 2025

Charles River Laboratories International, Inc. (NYSE:CRL) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 53 hedge money portfolios held Charles River Laboratories International, Inc. (NYSE:CRL) astatine the extremity of the 4th quarter, up from 50 successful the erstwhile quarter. While we admit the imaginable of Charles River Laboratories International, Inc. (NYSE:CRL) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article